- Home
- NCZ vs INBX Comparison
NCZ vs INBX Comparison
Compare NCZ & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCZ
- INBX
- Stock Information
- Founded
- NCZ 2003
- INBX 2010
- Country
- NCZ United States
- INBX United States
- Employees
- NCZ N/A
- INBX N/A
- Industry
- NCZ Finance Companies
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- NCZ Finance
- INBX Health Care
- Exchange
- NCZ Nasdaq
- INBX Nasdaq
- Market Cap
- NCZ 240.5M
- INBX 222.5M
- IPO Year
- NCZ N/A
- INBX 2020
- Fundamental
- Price
- NCZ $3.07
- INBX $13.85
- Analyst Decision
- NCZ
- INBX Hold
- Analyst Count
- NCZ 0
- INBX 1
- Target Price
- NCZ N/A
- INBX N/A
- AVG Volume (30 Days)
- NCZ 533.0K
- INBX 58.0K
- Earning Date
- NCZ 01-01-0001
- INBX 08-13-2024
- Dividend Yield
- NCZ 12.16%
- INBX N/A
- EPS Growth
- NCZ N/A
- INBX N/A
- EPS
- NCZ N/A
- INBX 119.38
- Revenue
- NCZ N/A
- INBX $1,568,000.00
- Revenue This Year
- NCZ N/A
- INBX N/A
- Revenue Next Year
- NCZ N/A
- INBX N/A
- P/E Ratio
- NCZ N/A
- INBX $0.12
- Revenue Growth
- NCZ N/A
- INBX 19.24
- 52 Week Low
- NCZ $2.50
- INBX $10.80
- 52 Week High
- NCZ $3.15
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- NCZ 48.25
- INBX 30.41
- Support Level
- NCZ $3.06
- INBX $15.97
- Resistance Level
- NCZ $3.24
- INBX $17.41
- Average True Range (ATR)
- NCZ 0.05
- INBX 0.85
- MACD
- NCZ 0.00
- INBX -0.25
- Stochastic Oscillator
- NCZ 46.15
- INBX 0.00
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas and consumable fuels and others.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.